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OBJECTIVES We prospectively evaluated the relation between cardiac troponin T (cTnT) level, the
presence and severity of coronary artery disease (CAD) and long-term prognosis in patients
with chest pain but no ischemic electrocardiographic (ECG) changes who had short-term
observation.
BACKGROUND Cardiac TnT is a powerful predictor of future myocardial infarction (MI) and death in
patients with ECG evidence of an acute coronary syndrome. However, for patients with chest
pain with normal ECGs, it has not been determined whether cTnT elevation is predictive of
CAD and a poor long-term prognosis.
METHODS In 414 consecutive patients with no ischemic ECG changes who were triaged to a chest pain
unit, cTnT and creatine kinase, MB fraction (CK-MB) were evaluated $10 h after symptom
onset. Patients with adverse cardiac events, including death, MI, unstable angina and heart
failure were followed for as long as one year.
RESULTS A positive (.0.1 ng/ml) cTnT test was detected in 37 patients (8.9%). Coronary artery
disease was found in 90% of 30 cTnT-positive patients versus 23% of 144 cTnT-negative
patients who underwent angiography (p , 0.001), with multivessel disease in 63% versus 13%
(p , 0.001). The cTnT-positive patients had a significantly (p , 0.05) higher percent
diameter stenosis and a greater frequency of calcified, complex and occlusive lesions.
Follow-up was available in 405 patients (98%). By one year, 59 patients (14.6%) had adverse
cardiac events. The cumulative adverse event rate was 32.4% in cTnT-positive patients versus
12.8% in cTnT-negative patients (p 5 0.001). After adjustment for baseline clinical
characteristics, positive cTnT was a stronger predictor of events (chi-square 5 23.56, p 5
0.0003) than positive CK-MB (.5 ng/ml) (chi-square 5 21.08, p 5 0.0008). In a model
including both biochemical markers, CK-MB added no predictive information as compared
with cTnT alone (chi-square 5 23.57, p 5 0.0006).
CONCLUSIONS In a group of patients with chest pain anticipated to have a low prevalence of CAD and a good
prognosis, cTnT identifies a subgroup with a high prevalence of extensive and complex CAD
and increased risk for long-term adverse outcomes. (J Am Coll Cardiol 2000;35:1827–34) ©
2000 by the American College of Cardiology
Previous studies have convincingly demonstrated that in
patients with chest pain, ischemic electrocardiographic
(ECG) changes and a high clinical suspicion of an acute
coronary syndrome (ACS) (e.g., myocardial infarction [MI]
or unstable angina [UA]), cardiac troponins T (cTnT) and
I (cTnI) are powerful independent predictors of MI or death
during follow-up (1–6). However, many of the five million
people with chest pain who present each year to the
emergency department (ED) in U.S. hospitals have normal
or nondiagnostic ECGs (7–9). Indeed, the frequency of
ECG changes indicative of ischemia or infarction in a large
population with acute chest pain evaluated in the ED was
reported to be only 26% (8). Therefore, the diagnosis of
acute MI or ischemia based on presenting symptoms and
the ECG is often challenging. Consequently, as many as
two-thirds of patients with chest pain are admitted from the
ED for “rule-out MI evaluation” or referred for short-term
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observation in specialized chest pain units (CPUs) (10,11).
Only a minority of these patients without ischemic ECG
changes are ultimately diagnosed with ischemic heart dis-
ease (9,12–14), and, typically, ,7% are diagnosed with MI
on the basis of cardiac enzymes (15). These patients
generally have excellent short- and long-term prognoses
(14,16,17). However, those who have elevated creatine
kinase (CK), and CK-MB fraction (CK-MB) levels are at
increased risk for recurrent ischemia, MI and death
(8,16,18).
Although cardiac troponin levels are often measured in
this setting, to our knowledge there are no published studies
addressing their long-term prognostic value in patients with
chest pain but no ECG evidence of acute myocardial
ischemia. In addition, no data are available on the relation
between troponin levels and the prevalence and severity of
coronary artery disease (CAD) in such a population.
This prospective study was undertaken in patients with
chest pain but no ischemic ECG changes who were triaged
to a CPU with the following aims: 1) to assess the incidence
of cTnT elevation; 2) to describe coronary angiographic
features in relation to cTnT levels; and 3) to evaluate the
additional prognostic value yielded by cTnT over CK-MB
and traditional clinical risk factors for predicting long-term
adverse cardiac events.
METHODS
Study patients. The study group consisted of 414 consec-
utive patients referred to the CPU from January 1996
through February 1997 at the University of Texas Medical
Branch at Galveston, a 938-bed, tertiary health care facility.
For acceptance to the CPU, the patient was required to have
,7% probability of an acute MI, as determined by the
algorithm developed by Goldman et al. (15). This required
the absence of new ST segment or T wave changes
diagnostic or suggestive of myocardial injury or ischemia.
Patients with ECG confounders (left bundle branch block
or ventricular paced rhythm) were excluded because they
had been shown to be at high risk for in-hospital ischemic
complications (1,3). Additional exclusion criteria included
systolic blood pressure .200 mm Hg or ,90 mm Hg; three
or more beats of ventricular tachycardia; evidence of heart
failure; febrile illness; or any comorbid disorder that would
prolong the patient’s hospital stay beyond a 23-h observa-
tion period. The study protocol was approved by the
Institutional Review Board of the University of Texas
Medical Branch at Galveston.
Clinical and ECG data collection. Data regarding the
quality, duration and frequency of chest pain, as well as
clinical risk factors, were collected in a prospective, stan-
dardized manner. On serial ECGs recorded before diagnos-
tic biochemical testing, new ST segment elevation $0.2 mV
in the precordial leads or $0.1 mV in the limb leads and ST
segment depression $0.1 mV or T wave inversion were
exclusion criteria. All ECGs were interpreted independently
by two attending cardiologists who had no knowledge of the
cardiac marker results. A discrepancy between readers re-
sulted in exclusion of the patient from the study.
Biochemical markers of myocardial injury. All patients
had a visually interpreted qualitative Cardiac T Rapid Assay
(Roche Diagnostics, Indianapolis, Indiana), quantitative
cTnT (ES-300 Instrument, Roche Diagnostics), total CK
activity and CK-MB mass (Stratus II Instrument, Dade,
Miami, Florida) drawn simultaneously at $10 h after the
onset of chest pain or $10 h after presentation if the time
of symptom onset was uncertain. The CK, CK-MB and
cTnT rapid assay results were available for clinical decision-
making. The qualitative cTnT rapid assay has a lower limit
of detection (0.18 to 0.2 ng/ml), as described by the
manufacturer and published elsewhere (19). The quantita-
tive cTnT results were determined using the ES-300 in-
strument and Cardiac-T ELISA Troponin T reagents.
Initially, when this study was conceived, an abnormal
quantitative cTnT value was considered to be .0.2 ng/ml
(6). On the basis of data published during the enrollment
period (3), a quantitative cTnT value .0.1 ng/ml was
considered positive in this study. The 200 patients studied
after July 1996 also had cTnT values reported using the
Enzymun-Test second-generation assay (Enzymun assay)
run on the ES-300 instrument. There were no individual
discrepancies between the two assays that crossed over the
cutoff of 0.1 ng/ml. Because of the higher discriminator
value of the qualitative cTnT rapid assay, all results reported
in this study are based on quantitative cTnT ELISA assay
results. A CK-MB mass .5 ng/ml was considered positive.
Coronary angiography. All patients with a positive cTnT
rapid assay (n 5 22) or CK-MB (n 5 23) were referred for
coronary angiography. In addition, a large cohort (n 5 150)
with a negative cTnT test underwent angiography for the
following reasons: 1) randomization to immediate cardiac
catheterization, as part of a long-term resource utilization
protocol (n 5 99) (14); and 2) clinical indications for
angiography, including positive noninvasive stress test (n 5
25), a known history of MI or CAD (n 5 20) and
physician’s discretion (n 5 6).
Abbreviations and Acronyms
ACS 5 acute coronary syndrome
CAD 5 coronary artery disease
CPU 5 chest pain unit
CK 5 creatine kinase
CK-MB 5 creatine kinase, MB fraction
cTnI 5 cardiac troponin I
cTnT 5 cardiac troponin T
ECG 5 electrocardiogram, electrocardiographic
ED 5 emergency department
MI 5 myocardial infarction
UA 5 unstable angina
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Cine angiographic films were analyzed independently by
two experienced operators who had no knowledge of the
patients’ clinical information, cTnT and CK-MB values.
Differences were mediated by consensus. All diameter
stenoses visually estimated as $50% underwent quantitative
coronary analysis performed with a digital caliper by one
observer (Mitutoyo Corp., Tokyo, Japan). The accuracy of
this method has been validated previously and compares
well with computerized methods (20). Based on 40 ran-
domly selected coronary segments in eight patients, the
intraobserver intraclass correlation coefficient was 0.98 (95%
confidence interval [CI] 0.97 to 0.99) and the interobserver
intraclass correlation coefficient was 0.99 (95% CI 0.99 to
1.0) for caliper measurements in our laboratory.
The lesions were assessed in two orthogonal views that
had the least vessel overlap and foreshortening using end-
diastolic frames, and the projection showing the smallest
lumen diameter was selected for measurements. The mean
of three measurements of minimal lumen diameter and
angiographically normal reference diameters proximal and
distal to the lesion were used to calculate the percent
diameter stenosis. Significant CAD was defined as $70%
lumen narrowing of a major epicardial artery or its branches.
In classifying the number of diseased vessels, a left main
stenosis $50% was regarded as equivalent to two-vessel
disease. Stenosis location was evaluated by utilizing a
simplified coronary tree scheme, as previously described
(21). Lesion length was measured as the distance from the
proximal to the distal lesion shoulder. Complex lesion mor-
phology was defined as any significant stenosis with over-
hanging edges or irregular borders, including lesion ulcer-
ation or severe, diffuse irregularities. Intraluminal thrombus
was defined as a filling defect, usually globular in shape, with
surrounding homogeneous contrast opacification in three or
more sides and identification in multiple views (22).
Follow-up and adverse cardiac events definition. Pa-
tients were followed-up for a minimum of six months by
telephone interviews. Adverse events were defined as fol-
lows: 1) death from any cause; 2) cardiac death, defined as
sudden, unexplained death or death related to MI, heart
failure or arrhythmia without a secondary cause; 3) nonfatal
MI, defined as chest pain associated with a positive CK-MB
test with return to a normal value; and 4) the need for
hospital admission owing to UA (rest or accelerating chest
pain associated with CAD determined by either angiogra-
phy, a positive noninvasive stress test or new ST-T wave
changes on the ECG) or heart failure (signs or symptoms of
congestion believed to be secondary to cardiac dysfunction).
The diagnosis and hospital periods were also evaluated by
review of the hospital records, when available.
Statistical analysis. Continuous variables are expressed as
the mean value 6 SD. The Student t test and the chi-square
test with Yates’ correction were used to compare differences
between groups for continuous and categoric data, respec-
tively. Survival and freedom from adverse events were
estimated using life-table survival techniques and compared
using the log-rank test.
Cox proportional hazard modeling was used to examine
individual and joint relations between clinical and biochem-
ical variables and the binary outcome (cumulative adverse
cardiac events at one year). The proportional hazards
assumption was verified by excluding a crossover between
survival curves for each binary variable. Conformity to the
assumption of a linear gradient for continuous or ranked
variables was graphically examined by plotting the observed
and predicted values for the outcome over the range of each
predictor. We found no significant change in the odds ratios
over time. Therefore, analyses include outcomes over the
entire duration of follow-up. Given the limited number of
events, only the significant univariate correlates were en-
tered into the multivariate analyses to minimize the risk of
model overfitting. The predictive ability of multivariate
models was expressed through the likelihood ratio chi-
square value. The incremental prognostic information
yielded by cTnT and CK-MB over clinical variables was
assessed by the change in the chi-square obtained by adding
each biochemical variable to a clinical model. The stability
of the risk estimates was internally verified through boot-
strap procedures. For all tests, a two-sided p value , 0.05
was regarded as significant. Computations were performed
using the Statistica, version 5.1 (StatSoft Inc.) software
package.
RESULTS
Clinical characteristics. Of the 414 study patients, cTnT
was positive in 37 (8.9%) (0.89 6 0.99 ng/ml, median 0.48
ng/ml) and negative in 377 (91.1%). Their clinical charac-
teristics are compared in Table 1. Patients with positive
cTnT tests were significantly older and more frequently
male, had a higher incidence of diabetes and more fre-
quently presented with typical chest pain.
Coronary angiographic findings. Among the 37 cTnT-
positive patients, 32 underwent coronary angiography. Of
the five patients who did not, four had a negative cTnT
rapid assay and CK-MB, and one patient refused. Two of
32 patients had previous coronary artery bypass graft surgery
with native three-vessel disease and were excluded from the
angiographic analysis. Of the remaining 30 patients, 27
(90%) had significant CAD, 19 of whom (63%) had
multivessel disease. Only three patients did not show $70%
coronary stenoses. Two of these patients had two-vessel
stenoses of 40% to 60%, no regional wall motion abnormal-
ities and a positive CK-MB test that subsequently returned
to normal, suggesting myocardial injury. The other patient
had no angiographic evidence of CAD and no regional wall
motion abnormalities, but had end-stage renal disease and
continued to have a persistently elevated CK-MB level.
Among the 377 cTnT-negative patients, 150 underwent
coronary angiography. Of these, six had previous bypass
surgery and were excluded from the angiographic analysis.
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Of the remaining 144 patients, 33 (23%) had significant
CAD, 19 of whom (13%) had multivessel disease.
Table 2 compares the angiographic findings of the 30
cTnT-positive patients with those of the overall group of
144 cTnT-negative patients and with a subgroup of 99
patients with negative cTnT test who were randomly
assigned to angiography (as outlined in Methods). The
prevalence and extent of CAD were significantly greater in
patients with a positive cTnT test than in those with a
negative cTnT test, either in the overall group or the
subgroup randomized to coronary angiography.
As shown in Table 3, cTnT-positive patients had a
significantly higher percent diameter stenosis and a greater
frequency of calcified lesions, occlusive lesions and stenoses
with a complex morphology. Intracoronary thrombus was
not identified in any of our patients.
Patient outcomes. During the initial hospital period, there
were no deaths; coronary revascularization was performed in
16 (43%) of 37 cTnT-positive patients versus 11 (3%) of
377 cTnT-negative patients (p , 0.001). Long-term
follow-up (mean 11 6 3.7 months) was obtained in 405
(98%) of 414 patients, including all cTnT-positive and 368
cTnT-negative patients. Overall, there were 59 (14.6%)
adverse cardiac events, including 2 deaths (0.5%), 5 MIs
(1.2%) and 52 hospital admissions for UA (n 5 46, 11.3%)
or heart failure (n 5 6, 1.5%). One patient died of
noncardiac causes (suicide).
Figure 1 illustrates the incidence and time distribution of
adverse events in patients with a positive or negative cTnT
test. The life-table survival plot shows separation of the
curves after one month and a difference in events that
modestly widened throughout the course of one year.
Freedom from any adverse event at 12 months was 66% in
cTnT-positive versus 87% in cTnT-negative patients (p 5
0.0004). Freedom from cardiac death or MI was 95% in
cTnT-positive versus 99% in cTnT-negative patients (p 5
0.03).
Figure 2 illustrates the relations between cTnT and
CK-MB results and the occurrence of long-term adverse
events. For the 368 cTnT-negative patients, the concor-
dance with negative simultaneous CK-MB was high (99%).
However, only 54% of the patients with a positive cTnT test
had a simultaneous positive CK-MB test. The cumulative
adverse event rate in cTnT-positive patients was 32.4% (12
of 37 patients), significantly higher (p 5 0.001) than that of
12.8% (47 of 368) in cTnT-negative patients. The 30% (7 of
Table 1. Baseline Characteristics of Patients With a Positive or Negative Cardiac Troponin
T Result
Positive cTnT
(n 5 37)
Negative cTnT
(n 5 377)
p
Value
Age (yrs) 59 6 14 51 6 11 0.0001
Male 21 (57%) 177 (47%) 0.003
Typical angina 17 (46%) 75 (20%) 0.0006
Diabetes mellitus 17 (46%) 90 (24%) 0.006
Hypertension 24 (65%) 211 (56%) NS
Hypercholesterolemia* 10 (36%) 87 (30%) NS
Family history 18 (49%) 196 (52%) NS
Smoking 19 (51%) 184 (49%) NS
History of MI 9 (24%) 60 (16%) NS
*Blood cholesterol was available in 28 cTnT-positive and 289 cTnT-negative patients.
Data are expressed as the mean value 6 SD or number (%) of patients.
cTnT 5 cardiac troponin T; MI 5 myocardial infarction.
Table 2. Prevalence and Extent of Coronary Artery Disease in Patients With a Positive or
Negative Cardiac Troponin T Result
Positive cTnT
(n 5 30)
Negative cTnT
Overall
(n 5 144)
Randomized to
Catheterization
(n 5 99)
Presence of CAD 27 (90%) 33 (23%)* 11 (11%)*
Extent of CAD
One vessel 8 (26%) 14 (9%)† 6 (6%)*
Two vessels 12 (40%) 14 (9%)* 4 (4%)*
Three vessels 7 (23%) 5 (3.5%)* 1 (1%)*
*p , 0.01 vs. positive cTnT. †p , 0.05 vs. positive cTnT.
Data are expressed as the number (%) of patients.
CAD 5 coronary artery disease; cTnT 5 cardiac troponin T.
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23 patients) event rate in CK-MB–positive patients was
higher, with a trend toward statistical significance (p 5
0.055), than that of 13.6% (52 of 382) in patients with a
negative CK-MB test.
Predictors of adverse events. Univariate Cox regression
models were estimated for each of the clinical variables
listed in Table 1. Four had a significant correlation with the
occurrence of adverse events within one year of initial
presentation: age $65 years, hypertension, diabetes and a
history of MI. These four variables, as predictors of adverse
events, formed our clinical model.
The prognostic impact of biochemical markers was tested
by estimating four multivariate Cox regression models that
included our significant clinical variables. The four multi-
variate models are listed in Table 4. The first model, the
clinical model, is a significant predictor of adverse events at
one year (likelihood ratio chi-square 5 18.49, p 5 0.001).
The addition of the CK-MB result (positive or negative) to
the clinical model showed a statistically significant joint
association with the five variables (p 5 0.0008), but the
increase in predictive ability in the clinical model was not
significant (change in chi-square: 21.08 2 18.49 5 2.59,
p 5 0.11). When the cTnT result (positive or negative) was
added to the clinical model, its contribution to risk strati-
fication was statistically significant (change in chi-square 5
5.07, p 5 0.024). Furthermore, a positive cTnT test was a
significant predictor of risk in this model (odds ratio [OR]
2.28, 95% CI 1.17 to 4.46; p 5 0.02). Finally, when both
Figure 1. Twelve-month life-table analysis plot for the combined
end point of cardiac death, nonfatal MI and readmission for UA or
congestive heart failure (CHF) in patients with a positive or
negative cTnT test. The number (%) of events is reported in the
inserted table.
Figure 2. Relation between cTnT and CK-MB at hospital admis-
sion and the occurrence of long-term adverse cardiac events (AE)
in patients with chest pain but no ischemic ECG changes.
Table 3. Angiographic Characteristics of Coronary Artery Lesions Associated With a Positive or
Negative Cardiac Troponin T Result
Positive cTnT
(n 5 68)
Negative cTnT
Overall
(n 5 62)
Randomized to
Catheterization
(n 5 16)
Coronary artery
LMCA 1 (1%) 1 (2%) 0
LAD 25 (37%) 22 (35%) 6 (38%)
LCx 22 (32%) 28 (45%) 5 (31%)
RCA 20 (29%) 11 (18%) 5 (31%)
Site
Proximal 25 (36%) 22 (35%) 5 (38%)
Midvessel 28 (42%) 28 (46%) 7 (44%)
Distal 15 (22%) 12 (19%) 3 (19%)
Percent diameter stenosis 89 6 12% 84 6 11%* 72 6 9%*
Calcification 13 (19%) 4 (6%)† 1 (6%)†
Occlusion 26 (38%) 7 (11%)* 2 (12%)*
Length .15 mm 14 (20%) 10 (16%) 2 (12%)
Thrombus 0 0 0
Complex morphology 35 (51%) 17 (27%)* 3 (19%)*
*p , 0.01 vs. positive cTnT. †p , 0.05 vs. positive cTnT.
Data are expressed as the mean value 6 SD or number (%) of lesions.
cTnT 5 cardiac troponin T; LAD 5 left anterior descending coronary artery; LCx 5 left circumflex artery; LMCA 5 left
main coronary artery; RCA 5 right coronary artery.
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biochemical markers were added to the clinical model, the
chi-square increase from the model with cTnT alone was
trivial (change in chi-square 5 0.01, p 5 0.92), indicating
that CK-MB provides no additional information. Figure 3
shows the individual ORs and 95% CIs from the multivar-
iate model, including clinical predictors and cTnT results.
In a subgroup analysis of patients with a negative
CK-MB test, the combination of clinical predictors and
cTnT results maintained a significant explanatory power
(chi-square 5 18.09, p 5 0.0029). In this model, a positive
cTnT test was the only significant predictor of adverse
events (OR 2.53, 95% CI 1.04 to 6.16; p 5 0.04).
DISCUSSION
To our knowledge, this study is the first to demonstrate that
in patients with chest pain but no ischemic ECG changes,
cTnT measurement provides better clinical and long-term
prognostic information than traditional clinical and bio-
chemical markers. First, in a group with an anticipated low
prevalence of ischemic heart disease, cTnT elevation iden-
tifies a group with severe and diffuse CAD and angiographi-
cally complex coronary morphology. Second, although our
results confirm that patients with chest pain but no ischemic
ECG changes have a low risk of future MI or cardiac death
(1,23,24), those with a positive cTnT test represent a subset
at relatively high risk, who show a continued increase in the
probability for cardiac events throughout one-year follow-up.
Cardiac TnT in low risk patients in the CPU. We
carefully selected patients at low risk for MI using the
previously validated Goldman algorithm (15). This is an
important distinction from the incidence of cTnT elevation
and its prognostic value in patients with ACS and ischemic
ECG findings reported in previous, large troponin studies
(2–6). Such patients have a prevalence of CAD .80% and
a high risk for acute MI (25). Compared with these previous
patients with ACS in whom the incidence of cTnT or cTnI
elevation ranges from 24% to 48% (2–6), cTnT was only
elevated in 8.9% of our patients, which is in keeping with
the 10% positive cTnT rate reported by Hamm et al. (1) in
a subgroup of patients with chest pain with normal ECGs
evaluated in the ED. In addition, our patients’ characteris-
tics also appear consistent with those of other patients in the
CPU, including a high prevalence of risk factors for CAD
(26).
Coronary angiographic findings. A unique aspect of our
report is the inclusion of extensive angiographic data.
Elevation of cTnT was correlated with angiographic evi-
dence of significant CAD in 90% of our patients and
intermediate CAD in an additional 6%. Furthermore,
cTnT-positive patients had predominantly multivessel dis-
ease, greater coronary narrowing and frequently complex
lesion morphology. These results are in keeping with data
from patients with ACS and ischemic ECG changes,
showing that positive cTnT results predict the presence of
complex and severely obstructive plaques (27). The fact that
angiographic features from our cTnT-positive patients are
similar to those observed in the majority of patients with
typical ACS presentations (22) suggests a common patho-
genesis, which, as previously reported, relates to plaque
disruption, with or without angiographically detectable
thrombus (28). Therefore, cTnT elevation indicative of
minor myocardial injury in patients with chest pain but no
ischemic ECG changes may represent part of a continuous
spectrum of ACS. We speculate that myocardial injury
either took place days before presentation or was the result
of microembolization, either of which might be missed by
the ECG or CK-MB assay.
Long-term risk stratification. Our study is the first to
address the long-term prognostic value of cTnT in low risk
patients with chest pain. The available data on the use of
cardiac troponins for short-term risk stratification in subsets
of patients with chest pain but no ischemic ECG changes
are controversial (1,29,30). Polanczyk et al. (29) reported
Figure 3. Adjusted odds ratios with 95% confidence intervals
determined by multivariate Cox regression analysis for factors
influencing the risk of long-term adverse cardiac events in a group
of patients with chest pain but no ECG changes.
Table 4. Ability of Multivariate Models to Predict One-Year Adverse Cardiac Events
df
LR Chi-
Square
p
Value
Clinical model* 4 18.49 0.001
Clinical model 1 CK-MB 5 21.08 0.0008
Clinical model 1 cTnT 5 23.56 0.0003
Clinical model 1 cTnT 1 CK-MB 6 23.57 0.0006
*Clinical model includes age $65 years, hypertension, diabetes mellitus and a history of myocardial infarction.
CK-MB 5 creatine kinase, MB fraction; cTnT 5 cardiac troponin T; df 5 degrees of freedom; LR 5 likelihood ratio.
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that cTnI was not a significant predictor of in-hospital
cardiac events. In contrast, Green et al. (30) found a positive
cTnT test to be a significant predictor of cardiac events at 14
days, but it provided no additional prognostic information
as compared with CK-MB. Although differences in the
patient groups studied and the choice of end points preclude
a direct comparison with the present study, our long-term
follow-up data extend the previous observations, showing
that the increased probability of adverse events in cTnT-
positive patients becomes evident during the first month of
follow-up and persists over one year. We found that after
accounting for differences in clinical risk factors, a positive
cTnT test conferred more than a twofold independent risk
for long-term adverse outcomes. Our results also suggest
that little information is to be gained by measuring CK-MB
levels in addition to cTnT in these patients.
It is significant that a relevant proportion of the events
(predominantly UA) occurred in patients who had both
negative cTnT and CK-MB tests. This is consistent with
the finding of Karlson et al. (17), who observed that .50%
of patients seen in the ED with chest pain and ischemic
heart disease, but not requiring admission, needed medical
attention for chest pain during the next year. Although
coronary angiographic features would probably have pre-
dicted the susceptibility to adverse events in these patients,
the modest event rate (13%) associated with a negative
cTnT test, along with a low incidence of CAD in this
group, suggests that a strategy of routine coronary angiog-
raphy is neither clinically justified nor cost-effective after a
low risk presentation. As in patients with ACS with
ischemic ECG changes, use of biochemical markers, such as
C-reactive protein, or routine stress testing before CPU
release may ultimately have a complementary role to cTnT
for risk stratification (31,32).
Study limitations. Several limitations of the present study
merit discussion. One is that a positive cTnT test was an
indication for coronary angiography. However, the inclu-
sion of nearly 100 cTnT-negative patients who were ran-
domly assigned to angiography should correct, in part, for a
“work-up” bias. This group can be expected to reflect the
anticipated low prevalence of CAD in a low-risk population
(9,12–14). The higher revascularization rate in cTnT-
positive patients, potentially driven by performance of rou-
tine angiography per protocol, may have ultimately im-
proved prognosis (33). Therefore, the ability of cTnT to
predict events may have been underestimated.
Reliance on coronary angiography may underrepresent
the frequency of intracoronary thrombus, as compared with
angioscopy (34). However, we detected no thrombi, which
may be related, in part, to our methods, including the
selection of patients (none of whom exhibited ECG
changes of ischemia) and the strict angiographic criteria for
detecting thrombus (22). Of note, in patients with UA, the
reported incidence of thrombus is highly variable, ranging
from 1% to 52% (35).
Obtaining immediate quantitative cTnT results was not
technically feasible at the time our study was performed;
thus, only bedside cTnT results were available to the
physician on duty. The unavailability of quantitative mark-
ers to clinicians is not without precedent. In previous large
studies evaluating the prognostic usefulness of cardiac tro-
ponins in high-risk patients, clinicians did not have access to
any troponin result and made decisions on the basis of
CK-MB values only (2–6). In our study, reliance on only
CK-MB mass would have resulted in many more cTnT-
positive patients inadvertently being excluded from the
angiographic protocol. However, because of the higher
cut-off value of the rapid assay, our analysis was based on
quantitative cTnT results, which today can be obtained
easily and quickly.
This study used the first-generation ELISA assay for
cTnT, which has been replaced by second- and third-
generation assays. These have a greater specificity for the
cTnT cardiac isoform (36). Approximately 50% of the
patients enrolled in the present study had both first- and
second-generation assays tested. There were no individual
discrepancies between the two assays that crossed over the
cut-off value of 0.1 ng/ml. Therefore, it is unlikely that the
greater specificity of the later generation assays would have
significantly impacted the results.
In the present study, clinical and ECG predictors are
used for triage and management until biochemical markers
are determined at 10 h after arrival or symptom onset. This
sampling time was specifically chosen to maximize the
sensitivity of both cTnT and CK-MB (37,38), which
appears appropriate to allow detection of minimal cardiac
marker rises such as those occurring in our low-risk group of
patients. Inclusion of an additional cTnT value on presen-
tation should not change the total number of patients with
positive tests, and therefore is unlikely to have an impact on
its prognostic value.
Lastly, as expected, the incidence of MI or cardiac death
was low during follow-up in our group (1,23,24). On the
basis of our event rates, a multivariate analysis of these end
points alone would have required a study of ;8- to 10-fold
magnitude (39), which is beyond the scope of a single-
institution experience.
Conclusions. For patients who had short-term observation
for chest pain in the absence of ischemic ECG changes,
cTnT elevation had a strong association with the presence
of severe and complex CAD. Prognostically, a positive
cTnT test is an independent and powerful predictor of
future adverse cardiac events. Therefore, cTnT measure-
ment should be an integral part of diagnostic workup in
these patients with chest pain, as it provides a simple
method to identify those at risk of future ischemic compli-
cations that would not otherwise be differentiated by clinical
history or CK-MB results. Further research will clarify
whether patients in the CPU with positive cTnT results will
1833JACC Vol. 35, No. 7, 2000 deFilippi et al.
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benefit from early and aggressive medical therapy, as is now
being administered to patients with ischemic ECG changes.
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